HCC

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

Based on data from a matching-adjusted indirect comparison study, cabozantinib the safety and efficacy of cabozantinib may be comparative to regorafenib in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.

Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.

"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."

“If we’re going to get patients to second-line treatment, we have to get them to front line. That has to do with transitioning patients from locoregional therapy appropriately."

Michael R. Charlton, MD, MBBS, discusses different types of therapy and trials in the hepatocellular carcinoma setting right now.

In an interview with Targeted Oncology, Lipika Goyal, MD, discussed the first- and second-line treatment options for patients with hepatocellular carcinoma and shared her thoughts on how these agents should be sequenced.

The combination of PD-L1 and VEGF inhibition suggests promise for the treatment of unresectable hepatocellular carcinoma, according to findings of the phase III IMbrave150 study.

In an interview with Targeted Oncology, Maria Reig, MD, PhD, discussed the results from the retrospective analysis of patients with hepatocellular carcinoma treated with nivolumab in the real-life setting in Spain.

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

In an interview with&nbsp;Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br /> &nbsp;

Patients harboring IDH1/2 muta&shy;tions may receive benefit by the use of PARP inhibitors, with investigators initi&shy;ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the&nbsp;Journal for ImmunoTherapy of Cancer.

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.

David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.

The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.

As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.

In an interview with&nbsp;Targeted Oncology, Augusto Villanueva, MD, discussed the role of driver mutations in patients with HCC and how liquid biopsies may help improve the treatment landscape in this patient population.

The FDA has granted Breakthrough Device designation to GALAD score, a serum biomarker-based device that predicts the probability that patients with chronic liver disease will develop hepatocellular carcinoma.

In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.

To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is addressing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.

In the community practice setting, patients with hepatocellular carcinoma who receive systemic therapy have a poor prognosis, which reveals an unmet need for more effective treatment options, according to a real-world retrospective observational study. The study aimed to show how treatment patterns related to the overall survival of patients with HCC throughout the United States.